Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

By L. Kappos, A. Bar-Or, B. Cree, R. Fox, G. Giovannoni, R. Gold, P. Vermersch, Douglas L. Arnold, S. Arnould, Tatiana Scherz and 317 more. The Lancet, 2018

796 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/653a6fa09b22699e28ea4a7eb58a04ade6365ef9